ClinicalTrials.gg
RecruitingNCT07453407ARTUpdated Aug 12, 2026

ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy

An interventional study of J-VALVE Transfemoral Aortic Valve system and Commercially available surgical biological aortic valve replacement device in Aortic Regurgitation, Aortic Valve Insufficiency and Aortic Insufficiency, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 28 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,250
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Aortic Valve Insufficiency with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · China.

Planned enrollment
Largest of 11
1,250 · median 116
Started
2026
with 4 others
No phase
10 of 23
7 open now
Primary completion
2029-03
later than 11 of 16 live
Registered
17th of 23
by date

Among the 23 studies in Aortic Valve Insufficiency with a site in China, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 11 of the 16 other live ones, and was the 17th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

17 of the 23 studies in Aortic Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Aortic Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

The overall purpose of ART trial is to establish the Safety and Efficacy of the J-VALVE Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients with Grade≥3+ Native Aortic Regurgitation.

03

Conditions studied

  • Aortic Regurgitation
  • Aortic Valve Insufficiency
  • Aortic Insufficiency

Keywords

  • Aortic Regurgitation
  • TAVR
  • SAVR
  • RCT
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Age ≥65 years;
  • 2) a. Symptomatic patients with severe AR b. Asymptomatic patients with severe AR and evidence of LV function impairment (per current ESC / ACC guidelines) Any of the following perimeters

    1. ≤55%
    2. LVESD >50 mm
    3. LVESDi >22 mm/m2
    4. LVESVi >45 mL/m2
    5. normal LV systolic function at rest (LVEF >55%), and a progressive decline in LVEF on at least 3 serial studies to the low-normal range (LVEF 55% to 60%) or a progressive increase in LV dilation into the severe range (LV end-diastolic dimension [LVEDD] >65 mm),
  • 3) Evaluated by a multi-disciplinary heart team to be suitable for both surgery and transcatheter valve replacement
  • 4) Informed of the nature of the study, agrees to its provisions, has provided written , and agrees to comply with all required post-procedure follow-up visits

Exclusion criteria

Exclusion Criteria:

  • 1. Confirmed moderate or less AR severity (Grade≤2+) by core laboratory evaluation
  • 2. Moderate or severe aortic valve stenosis
  • 3. Mixed with clinical relevant severe mitral or tricuspid disease that require valve intervention
  • 4. Pre-existing mechanical or bioprosthetic valve in any position. (of note, mitral ring is not an exclusion)
  • 5. Subject is high-risk for SAVR as determined by the local heart team
  • 6. Subject refuses SAVR as a treatment option
  • 7. Subject is selected for aortic valve repair or aortic surgery
  • 8. Need for emergency surgery or TAVR for any reason
  • 9. Anatomical exclusion criteria (ANY of the following):

    1. Aortic Annulus Perimeter \<53 mm or >94 mm measured by CT
    2. Maximal ascending aortic diameter ≥50 mm
    3. Congenital aortic valve disease including unicuspid, bicuspid, or quadricuspid aortic valve anatomy
    4. Iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath (e.g., calcification, tortuosity).
    5. Significant abdominal or thoracic aortic disease (such as porcelain aorta, severe calcification, aortic coarctation, etc.) that preclude safe passage of the delivery system or cannulation and aortotomy for surgical AVR.
  • 10. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of the screening visit
  • 11. Cardiac resynchronization therapy (CRT) device implantation within 30 days of the screening visit
  • 12. Any condition considered a to mechanical circulatory support
  • 13. Hostile chest or conditions or complications from prior surgery that preclude safe reoperation (e.g., mediastinitis, radiation damage, abnormal chest wall, adhesion of aorta or IMA to sternum, etc.)
  • 14. Subject refuses blood transfusion
  • 15. Marfan syndrome or other known connective tissue disease that would necessitate aortic root replacement/intervention
  • 16. Evidence of acute myocardial infarction within 30 days of the screening visit
  • 17. Any percutaneous coronary or peripheral interventional procedure performed within 30 days of the screening visit (Subjects with placement of coronary or peripheral stent(s) should be assessed for the ability to safely proceed with SAVR within the protocol timeframe)
  • 18. Complex coronary artery disease (one of the following):

    1. Unprotected left main coronary artery disease ≥50%
    2. True bifurcation lesion (Medina: 1.1.1) and the diameter of the branch vessels is >2.5 mm
    3. Chronic total occlusion (CTO)
    4. Long lesion, expected stent length >38 mm
    5. Multivessel lesion (at least 2 coronary arteries require interventional treatment)
    6. Need to use multiple stents (planned > 3 stents)
    7. Lesion with in-stent restenosis
    8. Severe calcification lesion
    9. Coronary ostial lesion
    10. Heart Team assessment that optimal revascularization cannot be performed with either CABG at the time of SAVR or PCI at the time of TAVR.
  • 19. Symptomatic carotid or vertebral artery disease or carotid intervention within 30 days of the screening visit
  • 20. Stroke or (TIA) within 90 days of the screening visit
  • 21. Severe left ventricular dysfunction, defined as a resting \<25%; or left ventricular end-systolic diameter (LVESD) >70 mm; or the presence of an artificial heart or left ventricular assist device; or being listed for heart transplantation or status post heart transplantation.
  • 22. Moderate to severe or worse right ventricular dysfunction on resting echocardiogram according to core laboratory
  • 23. Cardiac imaging (echocardiography, CT, and/or MRI) evidence of intracardiac mass, thrombus or vegetation
  • 24. Left atrial thrombus without continuous appropriate anticoagulation within 90 days of the study procedure
  • 25. Uncontrolled atrial fibrillation (i.e., resting heart rate >120 bpm)
  • 26. Hemodynamically significant hypertrophic Obstructive cardiomyopathy (HOCM), Peak LVOT gradient ≥50mmHg (resting or provoked) ESC 2022/ ACC 2020
  • 27. Untread Leukopenia (WBC\<3.0*109/L), Untread Thrombocytopenia ( count \<50*109), history of bleeding diathesis or coagulopathy, or hypercoagulable states, Acute posthemorrhagic anemia ( \<9.0 g/dL)
  • 28. Severe (COPD) ( \<50% predicted) or currently on home oxygen
  • 29. Severe pulmonary hypertension (e.g., PA systolic pressure ≥2/3 systemic pressure)
  • 30. Severe chronic liver disease ( C) or any active liver disease
  • 31. Renal insufficiency (\<30mL/min/1.73m²) and/or requiring chronic peritoneal dialysis at the time of screening and/or requiring chronic hemodialysis at the time of screening
  • 32. Ongoing sepsis or active infective endocarditis with ongoing antibiotic (including suppressive) therapy or positive blood cultures within 6 weeks
  • 33. Subject has a known or contraindication to all anticoagulation/antiplatelet medications (or inability to be anticoagulated for the index procedure), implant-related materials, or sensitivity to contrast media which cannot be adequately pre-medicated
  • 34. Inability to tolerate anti-thrombotic/anticoagulation therapy during or after the valve implant procedure
  • 35. Active gastrointestinal bleeding precluding anticoagulation or antiplatelet therapy
  • 36. >50 kg/m2 or \<18.5 kg/m2
  • 37. Estimated \<24 months due to associated non- cardiac comorbid conditions
  • 38. Immobility that would prevent completion of study procedures
  • 39. Currently participating in a cardiovascular drug or another device study and not yet completed follow-up for the primary endpoint. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. Observational studies are not considered exclusionary
  • 40. Severe cognitive decline (resulting in either inability to provide for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
  • 41. Pregnancy or intent to become pregnant (women suspected of becoming pregnant must have a negative serum or urine test for human chorionic gonadotropin before being included in the study)
  • 42. Other patients considered unsuitable for this clinical study by the investigator
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,250 participants (estimated)

Study arms

  • Experimental
    Transcatheter aortic valve replacement (TAVR)

    Transcatheter aortic valve replacement (TAVR) using J-VALVE Transfemoral Aortic Valve system

    Device: J-VALVE Transfemoral Aortic Valve system

  • Other
    Surgical aortic valve replacement(SAVR)

    Surgical aortic valve replacement(SAVR)using commercially available surgical biological aortic valve replacement device

    Device: Commercially available surgical biological aortic valve replacement device

Interventions

  • DeviceJ-VALVE Transfemoral Aortic Valve system

    Transcatheter aortic valve replacement (TAVR) using J-VALVE Transfemoral Aortic Valve system

  • DeviceCommercially available surgical biological aortic valve replacement device

    Surgical aortic valve replacement(SAVR)using commercially available surgical biological aortic valve replacement device

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    All-cause mortality at 12 months

    Time frame: 12 months

  2. All stroke

    Number of patients with stroke

    Time frame: 12 months

  3. Unplanned cardiac rehospitalization

    Number of patients who had unplanned cardiac rehospitalization

    Time frame: 12 months

Secondary outcomes

  1. New-onset atrial fibrillation

    Comparing the onset of atrial fibrillation in TAVR with SAVR

    Time frame: 30 days

  2. Echocardiographic effective orifice area

    Comparing echocardiographic effective orifice area in TAVR with SAVR

    Time frame: 30 days

  3. Moderate or greater patient prosthesis mismatch as measured by echocardiography

    Comparing moderate or greater patient prosthesis mismatched in TAVR with SAVR

    Time frame: 30 days

  4. Cardiovascular rehospitalization

    Comparing the number of cardiovascular rehospitalizations in TAVR with SAVR

    Time frame: 30 days

  5. Health-related quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ-23)

    Comparing change in KCCQ-23 in TAVR with SAVR. The KCCQ score ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: 30 days

  6. Length of index hospitalization

    Comparing TAVR length of index hospitalization with SAVR

    Time frame: Pre-intervention/procedure surgery

  7. Composite primary endpoints

    Comparing the superiority of the composite primary endpoint and its components in TAVR with SAVR

    Time frame: 30 days

Other outcomes

  1. Bleeding complications (life-threatening, disabling, or major)

    Comparing bleeding complications in TAVR with SAVR

    Time frame: 30 days, 6 months and 1 year

  2. Major adverse cardiovascular and cerebrovascular events (MACCE)

    Freedom of major adverse cardiovascular and cerebrovascular events

    Time frame: years 1, 2, 3, 4, 5, 6, 7, 8, 9, 10

  3. Mortality (all-cause & cardiovascular)

    Comparing mortality (all-cause \& cardiovascular in TAVR with SAVR

    Time frame: 30 days,6 months and years 1, 5, 10

  4. Stroke (disabling and nondisabling)

    Comparing stroke (disabling and nondisabling) in TAVR with SAVR

    Time frame: 30days, 6 months and years 1, 5, 10

  5. Death or stroke

    Comparing death or stroke in TAVR with SAVR

    Time frame: 1 year

  6. Death or disabling stroke

    Comparing death or disabling strokein TAVR with SAVR

    Time frame: 30 days, and 1 year

  7. Major vascular complications

    Comparing major vascular complications in TAVR with SAVR

    Time frame: 30 days

  8. Other procedural or valve-related complications

    Comparing other procedural or valve-related complications in TAVR with SAVR

    Time frame: 30 days

  9. Technical success

    Comparing technical success in TAVR with SAVR

    Time frame: Exit from procedure room

  10. Device success

    Comparing device success in TAVR with SAVR

    Time frame: 30 days

  11. Myocardial infarction

    Comparing myocardial infarction in TAVR with SAVR

    Time frame: 30 days, 6 months and 1 year

  12. Coronary obstruction requiring intervention

    Comparing coronary obstruction requiring intervention in TAVR with SAVR

    Time frame: 30 days, 6 months and 1 year

  13. Acute kidney injury

    Comparing acute kidney injury in TAVR with SAVR

    Time frame: 30 days

  14. Renal replacement therapy

    Comparing renal replacement therapy in TAVR with SAVR

    Time frame: 1 year

  15. New permanent pacemaker implantation

    Comparing new permanent pacemaker implantation in TAVR with SAVR

    Time frame: 30 days, 6 months and years 1, 5, 10

  16. Conduction disturbance and arrhythmias

    Comparing conduction disturbance and arrhythmias in TAVR with SAVR

    Time frame: 30 days,6 months and 1 year

  17. New York Heart Association class

    Comparing change in New York Heart Association class in TAVR with SAVR

    Time frame: 30 days, 6 months and years 1, 5, and 10

  18. Hemodynamic valve performance evaluated by echocardiography

    Comparing hemodynamic valve performance evaluated by echocardiography in TAVR with SAVR

    Time frame: 30 days, 6 months and at years 1, 2, 3, 4, 5, 7, 10.

  19. Other echocardiographic parameters

    Comparing other echocardiographic parameters in TAVR with SAVR

    Time frame: 30 days, and years 1, 2, 3, 4, 5, 7, 10.

  20. Cardiovascular rehospitalization

    Comparing cardiovascular rehospitalizations( the time to first event and number of events) in TAVR with SAVR

    Time frame: 30 days, 6 months,1 year, and annually until 10 years

  21. ICU days

    Comparing ICU days in TAVR with SAVR

    Time frame: Time from immediate post-operation to ICU discharge

  22. Redo valve replacement

    Comparing redo valve replacement in TAVR with SAVR

    Time frame: 30 days, 6 months,1 year, and annually until 10 years

  23. Six-minute walk test

    Comparing change in six-minute walk test in TAVR with SAVR

    Time frame: 30 days,6 months, and 1year

  24. Health-related Quality of Life as Assessed by KCCQ-23

    Comparing change in KCCQ-23 in TAVR with SAVR.The KCCQ score ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: 30days,6 months,1 year

  25. Early safety

    Comparing early safety in TAVR with SAVR

    Time frame: 30 days

  26. Clinical efficacy

    Comparing clinical efficacy in TAVR with SAVR

    Time frame: 1 year, and annually until 10 years

  27. Valve related long-term clinical efficacy

    Comparing valve related long-term clinical efficacy in TAVR with SAVR

    Time frame: 5 years and thereafter until 10 years

07

Study locations

2 of 28 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2026
First posted
Mar 6, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2038
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07453407
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Mar 5, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2038 (estimated)
Last update
Aug 12, 2026

Study contacts

Jian'an Wang, MD
Contact
wangjianan111@zju.edu.cn
+86-571-8778-4808
Jian'an Wang, MD
principal investigator · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion